Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1987 Jul;80(7):422–424. doi: 10.1177/014107688708000709

Adrenal suppression following low-dose topical clobetasol propionate.

E M Ohman 1, S Rogers 1, F O Meenan 1, T J McKenna 1
PMCID: PMC1290902  PMID: 3656312

Abstract

The use of topical steroids is associated with adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and application of more than 50 g per week of clobetasol propionate cream has been shown to cause secondary adrenal failure. We describe 4 patients who used clobetasol propionate cream over a prolonged period; 3 patients used less than 50 g per week (7.5, 25 and 30 g per week) and yet all developed secondary adrenal failure for up to 4 months after cessation of therapy. Adrenal insufficiency following prolonged use of clobetasol propionate in moderate dosages may therefore be more common than previously recognized. It is suggested that the metyrapone test, which conveniently examines the entire HPA axis, should be employed in patients receiving long-term topical clobetasol propionate cream and that glucocorticoid supplementation should be given during episodes of stress, such as infections and surgery, for up to 4 months after cessation of therapy.

Full text

PDF
422

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allenby C. F., Main R. A., Marsden R. A., Sparkes C. G. Effect on adrenal function of topically applied clobetasol propionate (Dermovate). Br Med J. 1975 Dec 13;4(5997):619–621. doi: 10.1136/bmj.4.5997.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carr R. D., Wieland R. G. Adrenocortical suppression with topical flumethasone. Arch Dermatol. 1967 Sep;96(3):269–272. [PubMed] [Google Scholar]
  3. Cooke J. N., Crow K. D. Pituitary-adrenal function after topical steroids. Lancet. 1967 Dec 9;2(7528):1254–1254. doi: 10.1016/s0140-6736(67)90591-0. [DOI] [PubMed] [Google Scholar]
  4. Cunningham S. K., Moore A., McKenna T. J. Normal cortisol response to corticotropin in patients with secondary adrenal failure. Arch Intern Med. 1983 Dec;143(12):2276–2279. [PubMed] [Google Scholar]
  5. FELDMANN R. J., MAIBACH H. I. PENETRATION OF 14C HYDROCORTISONE THROUGH NORMAL SKIN: THE EFFECT OF STRIPPING AND OCCLUSION. Arch Dermatol. 1965 Jun;91:661–666. doi: 10.1001/archderm.1965.01600120093023. [DOI] [PubMed] [Google Scholar]
  6. James V. H., Munro D. D., Feiwel M. Pituitary-adrenal function after occlusive topical therapy with betamethasone-17-valerate. Lancet. 1967 Nov 18;2(7525):1059–1061. doi: 10.1016/s0140-6736(67)90336-4. [DOI] [PubMed] [Google Scholar]
  7. Lehner T., Lyne C. Adrenal function during topical oral corticosteroid treatment. Br Med J. 1969 Oct 18;4(5676):138–141. doi: 10.1136/bmj.4.5676.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Meynadier J., Guillot B. Variations d'activité de l'axe hypophyso-surrénalien au cours du traitement par une crème au bénétonide de triamcinolone à 0,075 g%. Dermatologica. 1982 May;164(5):327–330. [PubMed] [Google Scholar]
  9. Munro D. D. The effect of percutaneously absorbed steroids on hypothalamic--pituitary--adrenal function after intensive use in in-patients. Br J Dermatol. 1976 Mar;94 Suppl 12:67–76. doi: 10.1111/j.1365-2133.1976.tb02272.x. [DOI] [PubMed] [Google Scholar]
  10. Riegelman S. Pharmacokinetics. Pharmacokinetic factors affecting epidermal penetration and percutaneous adsorption. Clin Pharmacol Ther. 1974 Nov;16(5 Pt 2):873–883. doi: 10.1002/cpt1974165part2873. [DOI] [PubMed] [Google Scholar]
  11. Scoggins R. B., Kliman B. Percutaneous absorption of corticosteroids: systemic effects. N Engl J Med. 1965 Oct 14;273(16):831–840. doi: 10.1056/NEJM196510142731601. [DOI] [PubMed] [Google Scholar]
  12. Staughton R. C., August P. J. Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate. Br Med J. 1975 May 24;2(5968):419–421. doi: 10.1136/bmj.2.5968.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Warde P., Powderly W. G., Fennelly J. J., Cunningham S., McKenna T. J. Hypothalamic-pituitary-adrenal function in patients receiving intermittent high dose prednisone therapy for lymphoma. Ir Med J. 1984 Feb;77(2):33–35. [PubMed] [Google Scholar]
  14. Wester R. C., Bucks D. A., Maibach H. I. In vivo percutaneous absorption of hydrocortisone in psoriatic patients and normal volunteers. J Am Acad Dermatol. 1983 May;8(5):645–647. doi: 10.1016/s0190-9622(83)70072-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES